Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Leukemia
Research conducted at Xencor, Inc. has updated our knowledge about leukemia
November 26th, 2008
According to recent research published in the journal Cancer Research, "CD19 is a pan B-cell surface receptor expressed from proB-cell development until its down-regulation during terminal differentiation into plasma cells. CD19 represents an attractive immunotherapy target for cancers of lymphoid origin due to its high expression levels on the vast majority of non-Hodgkin's lymphomas and some leukemias." "A humanized anti-CD19 antibody with an engineered Fc domain (XmAb5574) was generated to increase binding to Fc gamma receptors on immune cells and thus increase Fc-mediated effector functions. In vitro, XmAb5574 enhanced antibody-dependent cell-mediated...
Source: Immunotherapy Weekly (2008-11-26)
|
